Drug Development Research
Copyright © 2013 Wiley Periodicals Inc.
Edited By: Michael Williams
Impact Factor: 0.869
ISI Journal Citation Reports © Ranking: 2012: 54/59 (Chemistry Medicinal); 214/261 (Pharmacology & Pharmacy)
Online ISSN: 1098-2299
NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement
For additional tools visit Author Resources - an enhanced suite of online tools for Wiley Online Library journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.
Wiley's Journal Styles and EndNote
Note to NIH Grantees. Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate .
DRUG DEVELOPMENT RESEARCH documents all aspects of the research focusing on the discovery, development and post-marketing surveillance related to new therapeutic entities. The pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discover`y and development process. In addition to full-length articles, DRUG DEVELOPMENT RESEARCH publishes in-depth review articles. The journal will also feature periodic special thematic issues devoted to specific compound classes, disease areas, new technologies, and broad aspects of drug discovery and development. Submissions with data focused solely on in vitro physiochemical and pharmacokinetic data and do not contain any supporting pharmacodynamic data are outside the scope and intent of the journal and will not be considered for publication.
Statement of Responsibility
The opinions expressed and statements in articles, editorials or other materials in this journal are those of the authors. They are neither endorsed by nor represent official policy of the journal or the publisher, and neither shall have any liability in respect thereto. Neither the editor nor the publisher assumes any responsibility for any injury and/or damage to persons or property, as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. No suggested test, treatment or procedure should be carried out unless, in the reader’s sole and independent judgment, its use is appropriate and justified. Given that advances in medical science are rapid, it is recommended that independent verification of diagnoses, treatments, therapies and drug dosages be made. Discussions, views and recommendations as to medical procedures, treatments, therapies, choice of drugs, and drug doses are solely those of the authors, and not of the editor or the publisher.
What to submit
1. Digital file(s) only in Microsoft Word 2003 or higher via online submission. Please do not mail a hardcopy of the manuscript. If all programs used for the preparation of the manuscript are Microsoft Word-based, submissions must be made electronically to http://mc.manuscriptcentral.com/ddr.
2. Where necessary, copyright permission for use of data previously published must be submitted.
To submit your manuscript online to Drug Development Research, please
1. Prepare your manuscript and illustrations in the appropriate format according to the instructions below and those given at http://mc.manuscriptcentral.com/ddr under the "Instructions and Forms" button. Please also be sure that your paper conforms to the scientific and style instructions of the Journal, given below.
2. Check on the manuscript central site, to see if you are already in the system by simply clicking on the "Check for Existing Account" button, and follow the instructions given there. If you are not already in the system, create an account for yourself by clicking on the "Create an Account" button.
3. Before submitting, please be sure to carefully study the appropriate Instructions and Forms and then let the system guide you through the submission process. Online help is available to you at all times. You are also able to exit/re-enter the process at any stage before finally submitting your work.
All submissions are kept strictly confidential.
English, double-spaced in 10-point size type. Typeface is Arial or Helvetica.
Title page with:
- affiliation of authors with phone, fax, and e-mail information of corresponding author;
- running title with a maximum length of 50 characters including spaces;
- three to five keywords;
- funding/support information;
- total number of text pages, figures, tables.
Abstract: Maximum of 250 words on a separate page. Abstract should be intelligible without reference to the rest of the paper.
Text divided into:
- Methods and Materials;
Wiley's Journal Styles Are Now in EndNote
EndNote is a software product that we recommend to our journal authors to help simplify and streamline the research process. Using EndNote's bibliographic management tools, you can search bibliographic databases, build and organize your reference collection, and then instantly output your bibliography in any Wiley journal style.
Download Reference Style for this Journal: If you already use EndNote, you can download the reference style for this journal.
How to Order: To learn more about EndNote, or to purchase your own copy, click here .
Technical Support: If you need assistance using EndNote, contact firstname.lastname@example.org , or visit www.endnote.com/support .
References should be listed in alphabetical order with older papers cited first.
Tables with full legends on a separate page, numbered in Arabic in order of appearance, with a title, and keyed into text.
Legends to figures on a separate page, numbered in Arabic in order of appearance.
Figures should not duplicate information already presented in tabular form. Black and white figures and illustrations must be submitted in electronic format with the software used clearly identified. All graphics and lettering must be legible after reduction to 25% of original size. Figures must be numbered in order of appearance in the text with Arabic numerals. Color figures should be used sparingly and where the use of color is essential to conveying pertinent scientific information. Authors are responsible for the cost of color reproduction ($500 for each page printed in color) and must indicate agreement to pay such charges prior to acceptance of their paper. For best reproduction, bright, clear colors should be used. Dark colors against a dark background do not reproduce well; please place your color images against a white background wherever possible. Please contact Larry Graup via e-mail at email@example.com for further information. All graphics and lettering must be legible after reduction in size. Illustrations must be numbered in order of appearance with arabic numerals and keyed into the text. An illustration or group of illustrations should not exceed 6-3/4” wide by 8-3/4” long (approximately 17.1 cm by 22.2 cm).
Cite in text as Smith and Jones , Smith and Jones [2002a,b], or Smith et al. . Parenthetical citations appear as [Smith and Jones, 2002], etc. Abbreviations for journals used in the reference list should conform to Index Medicus . Refer to the following examples when preparing citations:
Journal Article (list all authors and avoid use of et al.):
Smith A, Jones B. 2002. Full article title. Jrnl Abbr 1:20–29.
Smith A, Jones B. 2002. Complete book title. New York: John Wiley & Sons. 300 p.
Chapter in Book:
Smith A. 2002. Full chapter title: including subtitle, if any. In: Jones B, editor. Book title in full. New York: Wiley-Liss. p 12-34.
Manuscripts for consideration by Drug Development Research must be submitted solely to this journal, and may not have been published in another publication of any type, professional or lay. The journal will not be responsible for loss of manuscripts at any time. Upon acceptance of a manuscript for publication, the corresponding author will be required to sign an agreement transferring copyright to the publisher. All such manuscripts become the property of the publisher, and no material published in Drug Development Research may be reproduced or published elsewhere without written permission from the publisher, who reserves copyright.
Conflict of Interest
Any possible conflict of interest, financial or otherwise, or the absence of conflict related to the submitted work must be clearly stated in a footnote on the first page of the submitted manuscript. Failure to provide this information will result in delays in the review process and/or automatic rejection.
Where applicable, the editorial office should receive assurance that work performed on human subjects complies with standards established by an appropriate ethics review committee (IRB in the United States) and the granting agency. If the manuscript includes data or description of humans, the authors must provide: a statement in the manuscript that (1) the research was prospectively reviewed and approved by a duly constituted Institutional Review Board (IRB) from the author's originating institute that adheres to state and/or federal guidelines for Informed Consent or (2) that the manuscript is a retrospective case report that does not require IRB approval at that institution. Failure to provide this information will result in delays in the review process and/or automatic rejection.
Manuscripts that describe results of vertebrate animal research must include a statement that the research was prospectively reviewed and approved by a duly constituted institutional animal care and use committee and adheres to the Guide for the Care and Use of Laboratory Animals . 8th Edition, National Academies Press, Washington, DC http://oacu.od.nih.gov/regs/guide/guide.pdf. Failure to provide this information will result in delays in the review process and/or automatic rejection.
All statements in, or omissions from, published manuscripts are the responsibility of authors, who will be asked to review proofs prior to publication. Reprint order forms will be sent with the page proofs. No page charges will be levied against authors or their institutions for publication in the journal.
The Journal strongly encourages authors to deliver the original submission and then the final, revised version of their accepted manuscripts (text, tables, and illustrations) digitally by using the Manuscript Central submissions system. Given the near-universal use of computer word-processing for manuscript preparation, we anticipate that this process will be convenient for you, and it carries the added advantages of maintaining the integrity of your keystrokes and expediting typesetting. Please contact the executive editor, Michael Williams at email: firstname.lastname@example.org or the production editor Larry Graup email@example.com for further information.
Guidelines for Electronic Submission
Software and format . Microsoft Word 6.0 or higher is mandatory. Pdf files will not be accepted for review. Refrain from complex formatting; the Publisher will style your manuscript according to the Journal design specifications.
File names . Submit the text, tables and figures of each manuscript as a single file . Name each file with your last name (up to eight letters). Text files should be given the three-letter extension that identifies the file format.
All print reproduction requires files for full color images to be in a CMYK color space. If possible, ICC or ColorSync profiles of your output device should accompany all digital image submissions.
Software and format . All illustration files should be in TIFF or EPS (with preview) formats. Do not submit native application formats.
Resolution . Journal quality reproduction will require greyscale and color files at resolutions yielding approximately 300 ppi. Bitmapped line art should be submitted at resolutions yielding 600-1200 ppi. These resolutions refer to the output size of the file; if you anticipate that your images will be enlarged or reduced, resolutions should be adjusted accordingly.
File names . Illustration files should be given the 2- or 3-letter extension that identifies the file format used (i.e., .tif, .eps).
Reprints: Reprints may be purchased at https://caesar.sheridan.com/reprints/redir.php?pub=10089&acro=ddr
??? Production Questions ???